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Nonsurgical rhinoplasty with injectable fillers has become an increasingly popular
option in recent years. Their rise in popularity has been driven by a number of fac-
tors, including their minimally invasive nature and the cost lower than surgical option.
Physicians should keep in mind that there are many possible complications, especially
in the hands of a novice injector. Fortunately, most complications are minor and tran-
sient in nature, although the patient may consider them aesthetically displeasing and
unacceptable. Major complications are rare; however, an inadequate treatment can
produce transient to permanent damage for the patient. A review of the medical litera-
ture from 2002 was performed to gather information on main complications after nasal
injections using the databases of the National Library of Medicine, Ovid MEDLINE, and
Cochrane Library. Understanding the basic anatomical knowledge of the midface, espe-
cially the vascular system, is fundamental to prevent the appearance of complications.
However, recognize immediately the symptoms and know the correct treatment in
case of complications is the only way to minimize permanent bad outcome.
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1 | INTRODUCTION
The use of injectable fillers has increased its popularity as an alterna-
tive to facial cosmetic surgery, as reported by the International Soci-
ety of Aesthetic Plastic Surgery (International Society of Aesthetic
Plastic Surgery, ISAPS Global Statistics). Filler injections allow to
obtain excellent results owing their relatively easy nonsurgical deliv-
ery, rapid results, and low-cost office-based procedure.
Surgical rhinoplasty, according to ASAPS statistics (http: //www.
surgery.org/sites/default/files/ASAPS-Stats2016.pdf), is the sixth of the
most requested procedures; however, nonsurgical rhinoplasty with
fillers in the last few years has shown to be an effective alternative
for patients who looking for an aesthetic improvement of the nose.
Fillers can sculpt the nasal shape by injections in the space
between the skin and nasal skeleton and this technique called
“nonsurgical rhinoplasty” grown up during these years because
their effects are visible immediately after treatment and patients
can return to their normal activities on the same day. (Kim &
Ahn, 2012)
Although fillers generally are considered safe, complications may
occur including immunoreactions, infections and cellulitis, skin
necrosis, granuloma formations, and more severe adverse reactions
as ophthalmic and retinal artery occlusion or embolization (Daines &
Williams, 2013; Lazzeri et al., 2012; Park et al., 2012; Park, Seo,
Kim, & Chang, 2011).
Understanding the basic anatomical knowledge of the midface,
especially the vascular system, is fundamental to reduce the risk of
developing complications during nasal cosmetic injections.
With this review, we want to focus on the main complications asso-
ciated with nonsurgical rhinoplasty procedure and on their management.
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2 | METHODS
A literature search was performed to gather information on main com-
plications after nasal injections from reports published from 2002 up
to January 2018. The databases of the National Library of Medicine,
Ovid MEDLINE, and Cochrane Library were searched using the fol-
lowing Boolean string: (soft tissue augmentation OR filler OR inject-
able) AND (complication OR adverse event OR embolism). The search
was limited to the English language literature. In addition, the refer-
ences cited in the identified articles were reviewed to identify any
additional reports.
Reports of “moderate” and “severe” complications following use
of injectable filler were selected for this review; these included herpes
simplex virus infections, anaphylaxis, nodules and granulomas, soft-
tissue necrosis, filler embolization resulting in impending necrosis and
blindness.
The only filler materials included were those that had been approved
by the US Food and Drug Administration (FDA) at the time of the
review. These materials were collagen, hyaluronic acid (HA), polymeth-
ylmethacrylate suspended in collagen, calcium hydroxylapatite (CaHa),
poly-L-lactic acid, and injectable dermal matrix. Autologous fat, liquid sili-
cone, and other non-FDA-approved substances were excluded.
3 | NONSURGICAL RHINOPLASTY
3.1 | Anatomy
The success of nonsurgical rhinoplasty depends on the personal ability
of the injector, the anatomic characteristics of the patient's nose
(thickness and quality of the skin and the soft tissue, nasal size, shape,
and strength of the cartilage and bone) (Jung et al., 2000; Tardy Jr.,
1997) and the recognition of such individual variation.
A good knowledge of the soft tissue anatomy of the nose and its
vascular system represents the first step to minimize complications.
Before starting injection, the specialist should be aware of the fol-
lowing characteristic:
• The soft tissue of the nasal bridge is the thickest at the nasion and
the thinnest at the rhinion, which is the junction of the upper lat-
eral cartilages and the nasal bones.
• There are four layers between the skin and the bony–cartilaginous
framework: superficial fatty layer, fibromuscular layer, deep fatty
layer, and periosteum or perichondrium.
• A thicker and oily skin makes injections more difficult because post
treatment edema occurs more often and create a pleasing 3-D shape
is more challenging. However, an advantage of having thicker skin is
that minute irregularities or asymmetry is camouflaged more easily
compared with patients with thin skin.
• Major blood vessels of the external nose are located in the superfi-
cial muscular aponeurotic system (SMAS) layer or the superficial
fatty layer (Jung et al., 2000). Therefore, the ideal layer for filler
injection is the deep fatty layer located between the SMAS and the
perichondrium or periosteum to minimize the risk of embolization.
• The ophthalmic artery, a branch of the internal carotid artery, mainly
supplies blood to the upper part of the nose via the anterior ethmoid
artery and the dorsal nasal artery; the facial artery, a branch of exter-
nal carotid artery, gives rise to the angular and superior labial arteries
that supply the lower part of the nose. Here, we have two columellar
arteries following the medial cartilagineous crus; the nasal base hosts
the lateral nasal artery that creates a subdermal plexus; nasal tip hosts
columellar arteries and lateral nasal arteries create arcades; midline
hosts nasal dorsum and glabella where nasal dorsal arteries provide
vascularization from the angular and the ophthalmic arteries.
The main anatomical features of the nose and its vascular system
are represented in Figure 1.
3.2 | Nonsurgical rhinoplasty technique
The ideal and safe layer for filler injection is the deep fatty layer
located between the SMAS and the perichondrium or periosteum,
which maintain the amount of filler injected in the midline.
After comparing and examining the ideal nose shape and the
patient's nose shape, decide how to perform the injections. It is possi-
ble to proceed with or without any local anesthesia and for many
authors it can be useful to mark the midline to prevent the asymmetry
and the main vascular complications.
Filler is usually injected in the order of the radix; rhinion; tip; and,
finally, the supratip area (Figure 2).
Injection sites were the following:
• above the hump to ameliorate nasofrontal angle,
• above the anterior nasal spine to project the tip of the nose and
ahead of the anterior part of the medial crura to enhance columella,
• above the tip of the nose (by percutaneous or endonasal approach)
to reshape it and create a supratip break and above upper lateral
cartilages in case of deficiency.
The nasal dorsum should be treated using a threading technique
along the midline, injecting a small amount of HA and, after injection,
the HA should be gently massaged to avoid contour irregularities.
The nasal sidewall is treated using small amounts of HA, through a
crosshatching technique, with at least 15-minute post injection mas-
sage. Because of the high risk of vascular compromise, the skin of the
nasal sidewall should be continually assessed during injections.
More than any other area, the nasal tip skin must be treated with
small amounts of HA and constant assessment of skin perfusion to
avoid potentially disastrous sequelae of nasal tip skin compromission.
To be more conservative, preventing adverse reactions, and to pro-
ceed in a safely way in order to give the desired nasal shape, Injections
are performed using a small amount of filler through the linear threading
technique. Specialists can use a sharp needle or a blunt cannula; how-
ever, a blunt cannula is recommended for beginners because there is rel-
atively less possibility of complications such as intravascular injection.
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Volume range of the filler injected was between 0.2 and 1.5 mL
(Rohrich, Ghavami, & Crosby, 2007).
After injections, no special dressings no prescription for antibiotics
are needed.
3.3 | Complications of nonsurgical rhinoplasty
Although soft-tissue fillers have a very favorable safety profile, adverse
events can occur.
It is possible to classify complication in two groups:
1. Self-limited complications: relatively common and potentially
related to improper technique (Gladstone & Cohen, 2007; Lowe,
Maxwell, & Patnaik, 2005).
2. Severe complications: less frequent but more severe than the
reactions mentioned above. It is possible to group them based on
severity into minor and major and may appear early or delayed
compared to the time of cosmetic procedure.
3.3.1 | Self-limited complications
The most common complications after filler injections are swelling,
bruising, erythema, hypersensitivity, nodules, lump, and asy-
mmetry.
• Swelling and bruising are the main complications appearing imme-
diately after filler injections; they are caused by vascular damage
by the needle.
• Erythema is another common complication. Usually, it is transient
but sometimes may evolve in permanent telangiectasias requiring a
special treatment.
• Hypersensitivity; occasionally, related to the filler ingredients.
The main symptoms are pain and erythema, accompanied
by pruritus and fever. In most cases, the symptoms subside
as the causative substance disappears; sometimes they can
rarely lead to anaphylactic shock (Bergerat-Galley, Latouche, &
Illouz, 2001).
F IGURE 1 Anatomy of the
nose with the main point and
planes of injections (upper side).
The ideal and safe layer for filler
injection is the deep fatty layer
located between the SMAS and
the perichondrium or periosteum,
which maintains the amount of
filler injected in the midline.
Vascular system nasal-ophthalmic
(lower side). Note the dense
anastomotic system between the
nasal arteries and the ophthalmic
arteries, such that intravascular
injections can result in serious
complications such as blindness
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• Nodules; their development is a common complication due to the
use of fillers for soft tissue augmentation and commonly they are
categorized as inflammatory or noninflammatory. Inflammatory
nodules may appear anywhere from days to years after treatment,
whereas noninflammatory nodules are typically seen immediately
after implantation and are usually secondary to improper place-
ment of filler.
• Lumps can form after filler injection; these are due to either granu-
loma or nodule formation. A granuloma is an immune-mediated
response to an injected foreign body and is formed by accumulation
of immune response-related cells, such as lymphocytes, to eliminate
the foreign body (Matarasso, Carruthers, & Jewell, 2006).
• Asymmetry is one of the most common complications of non-
surgical rhinoplasty. To prevent it, the needle must be placed pre-
cisely in the midline, and the direction of the bevel should be toward
the median plane. When injecting filler to correct a deviated nose, it
is prudent to watch the shape of the nose closely while slowly
injecting small amounts of filler to prevent an improper placement
of the filler.
3.3.2 | Severe complications
Severe complications are not so frequent but may cause serious
discomfort to the patient and require, in most cases, specific and
prolonged treatments. They may appear early or delayed, after the
cosmetic procedure and not always resolve completely, remaining
in partial or total functional limitations. The most common severe
complications are granulomas and vascular embolism causing skin
necrosis or visual impairment.
• Granuloma is a rare delayed major adverse event. These have been
reported to occur in roughly 0.1% of the patient population, mostly
after the injection of permanent or semipermanent fillers (Lowe
et al., 2005). They usually occur within the first 6 months after
injection but can also occur as late as years after.
• Skin necrosis is one of the most severe and feared early-occurring
complication, due to interruption of the vascular supply to the area
by direct injury of the vessel, compression of the area around the
vessel, or obstruction of the vessel by the filler material (Georgescu,
Jones, McCann, Anderson, & Anderson, 2009)
This process is often associated with prolonged blanching and possi-
bly pain at the site of injection, followed later by a dusky discolor-
ation, although Hirsch and colleagues reported on an impending
necrosis with the first symptom presenting only 6 hours after injec-
tion and a dusky purple discoloration of the affected area (Park
et al., 2012).
The dorsal and external nasal arteries are also branches of the oph-
thalmic artery, which also provide collateral flow to the nasal tip. Iso-
lated reports of tip necrosis have been published in the literature
following the use of fillers of all types, and it has been documented
as a rare complication of surgical rhinoplasty.
The mechanism behind this is assumed to be compression, occlu-
sion, and/or embolization of these vessels (Grunebaum, Bogdan
Allemann, Dayan, Mandy, & Baumann, 2009). These events are
clearly not unique to the nasal vessels, with similar reports seen
following administration of fillers in the forehead, glabellar, temple,
and the nasolabial region (Carruthers, Fagien, Rohrich, Weinkle, &
Carruthers, 2014).
• Vision impairment and the consequent blindness are the worst
severe complications of filler injections. Blindness after filler's
injection is extremely rare and was first reported by von Bahr more
than 50 years ago. These complications are caused by an acciden-
tal intravascular injection of filler that, especially at nasal dorsum,
glabella (dorsal nasal artery) and on the sidewall of the nose (angu-
lar artery), if carried out with sufficient pressure, can enter in the
supratrochlear or supraorbital arteries. Filler particles can retro-
gradely reach the origin of the artery to the ophthalmic artery. Fol-
lowing systolic pressure, filler can be transported along the
ophthalmic artery or the central artery of the retina, causing a sud-
den loss of vision.
In 2012, Lazzeri et al. conducted a systematic review on iatrogenic
blindness after facial cosmetic injections, they reviewed clinical
data of 32 patients, and suggested some precautions to avoid such
complications (Lazzeri et al., 2012). Similarly, Park and his col-
leagues enrolled 44 patients in a Korean national survey and inves-
tigated their clinical manifestations and visual prognosis of retinal
artery occlusion resulting from the surgery (Park et al., 2012). In a
recent review by Li et al. 75 cases of blindness secondary to facial
F IGURE 2 Four steps of nonsurgical rhinoplasty
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injections were recorded; 25% of the cases were secondary to
nasal dorsum injections (Li, Du, & Lu, 2015). The hypothesis pro-
posed by the authors is based on the presence of an anastomosis of
the nasal area, consisting of a dorsal nasal artery from the ophthalmic
artery, an angular artery, and a lateral nasal artery from the facial
artery. Schanz et al. also underlined the importance of a good knowl-
edge of standard vascular and its variant is essential to avoid vascular
complications not only represented by nasal skin necrosis but also by
blindness (Schanz, Schippert, Ulmer, Rassner, & Fierlbeck, 2002).
HA filler are more frequent related to blindness by a study conducted
by Beleznay et al. in 2015 (23% instead of 2% related to the use of
CaHA in a group of 98 patients). Probably, this could be related to the
use more frequent of this kind of filler instead of the kind of material
used (Beleznay, Carruthers, Humphrey, & Jones, 2015).
Consequence of all these studies, it is common the use of cannula
instead of needle to reduce the risk of vascular embolism and prevent
these severe complications.
3.4 | Management of complications
The injections of dermal filler, if carried out with the right precautions,
are safe and the associated complications are minimal. However,
F IGURE 3 Management of complication after nonsurgical rhinoplasty. Complication after cosmetic procedure using filler is rare. However,
when occur, it is necessary to recognize them immediately in order to intervene with the most appropriate treatment depending on the onset, the
severity of complication and the kind of filler injected (hyaluronidase should be used only after HA filler injections)
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when appear, complications should be immediately recognized and
correctly treated. It is fundamental remind that prevention is always
better and easier than treatment.
Generally, to prevent adverse events filler should be injected
slowly and gently, and we suggest the use of 27G 13 mm needle or
38 mm 25G cannula. It is essential to aspirate to verify a negative
flashback before making any filler injection. To minimize intravascular
injection in nose augmentation, the filler should be placed along the
midline of the radix, dorsum, supratip, and nasal spine, and below the
subcutaneous and musculoaponeurotic system layer, in which the
major vasculature of the nasal skin is located (Humphrey, Arkins, &
Dayan, 2009).
However, when occur, it is necessary to recognize them immedi-
ately in order to intervene with the most appropriate treatment. An
algorithm for treatment of mild-to-severe complication following filler
injection is reported in Figure 3.
3.4.1 | Management of self-limited complications
Transient self-limited complications usually do not cause serious dis-
comfort to the patient. They appear immediately (bruising, swelling,
and ecchymosis) or a few hours after the cosmetic procedure (ery-
thema) and resolve spontaneously within a few days without need of
any therapy but just following some good rules (De Boulle, 2004).
To reduce this kind of adverse events, piercing of muscular layers
must be minimized during filler injection and the injection site should
accurately cleaned with an alcohol swab. Patients should be informed
not to take blood thinners, such as aspirin, 1 week before the proce-
dure and the application of ice packs on the injection site immediately
post procedure helps minimize the appearance of these adverse reac-
tions (Rohrich, Monheit, Nguyen, Brown, & Fagien, 2010).
If bleeding occurs during procedure, the injection site should be
covered with gauze and pressed for several minutes to avoid the for-
mation of a hematoma.
After cosmetic injections, patients should avoid direct sun exposure,
hot-humid places (saunas, spas, swimming pools), intense physical activ-
ity and, in the early hours, the application of cosmetic products.
When erythema evolves in permanent telangiectasias, a treatment
with intense pulsed light therapy or pulsed dye laser is required
(Sclafani & Fagien, 2009).
3.4.2 | Management of severe complications
Nodules and erythema that persist beyond the first few days of treat-
ment may be signs of inflammation (Lemperle & Duffy, 2006; Rohrich
et al., 2010).
In these cases, massage, antibiotic therapy, and administration of
hyaluronidase for HA products have proven helpful (Sclafani &
Fagien, 2009).
As reported by Alam et al., true granulomas appear late, after
weeks or months, and they respond well to intralesional steroids or
incision and drainage. In case of mild/moderate complication (lumps,
asymmetries, nodules, or granulomas) due to HA filler, it is possible to
use hyaluronidase (Alam et al., 2008). The effective dosage depends
on the extent of the area to be treated: less than 2.5-mm area:
10–20 U single injection; area of 2.5 mm–1 cm: two to four injection
points with 10–20 U per injection point. In both cases, if required,
repeat injection (Signorini et al., 2016).
Vascular-related events are the complications most likely to result
in permanent sequelae, so an appropriate treatment should be started
immediately upon suspicion of vascular compromise.
Dayan et al. have suggested the use of hyaluronidase in all
cases of vascular compromise, independent of the filler type, due
to its edema-reducing benefits and theoretical advantage in reduc-
ing occluding vessel pressure. In his 5-year retrospective review,
he reported 2089 injectable soft-tissue filler treatments and just
41 cases of complications, most of them after injections with CaHA;
of these, 2 were severe cellulitis, 1 was a nodule formation, and
1 was a nasal sidewall skin necrosis related to nose treatment (injec-
tion of nasolabial fold). However, after treatment, he has demon-
strated the complete recovery of the patients (Dayan, Arkins, &
Mathison, 2011).
The consensus treatment in case of intravascular injections is
based on massaged and application of warm compresses to increase
vasodilatation (De Boulle, 2004). Utilization of nitroglycerine paste,
hyaluronidase and systemic or topical steroids to reduce associated
inflammation, may be useful (Alam & Dover, 2007; Sclafani & Fagien,
2009). De Lorenzi proposed a new protocol to manage acute filler
related vascular events. He called it HDPH High Doses Pulsed Hyal-
uronidase. The current protocol is exceedingly simple and involves
solely the use of hyaluronidase in repeated high doses. Despite the
simplicity of the treatment, it has proven itself to be very successful.
There has been no partial or complete skin loss associated with this
protocol since its implementation if the protocol was implemented
within 2 days of the ischemic event onset. The protocol involves diag-
nosis and repeated administration of relatively high doses hyaluroni-
dase into the ischemic tissue repeated hourly until resolution (as
detected clinically through capillary refill, skin color, and absence of
pain). The dosage of hyaluronidase varies as the amount of ischemic
tissue, consistent with the new underlying hypothesis that we must
flood the occluded vessels with a sufficient concentration of hyal-
uronidase for a sufficient period of time in order to dissolve the HA
obstruction to the point where the products of hydrolysis can pass
through the capillary beds. He used the rough rule of thumb, using the
lip, nose,and forehead as dose multipliers, with the standard dose of
about 500 iu per area. For a single region, he recommend starting with
a dose of about 500 iu every hour or so, until the ischemia is resolved
(until skin color has returned and capillary refill time has returned to
normal). For two areas, 1000 iu, and 1500 iu for three areas. Typically,
most resolved in three or four tretments sessions, but rarely
there have been up to 8 or 9 re-injections of hyaluronidase (De
Lorenzi 2017).
As reported by Kim et al., it is not so infrequent to have a
scarring outcome after skin necrosis. (Kim et al., 2011) He studied
how hyaluronidase could be useful in the treatment of skin necro-
sis; performing injections on rabbits, he showed that hyaluronidase
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reduced the vascular complications of HA fillers when used early,
but there was no benefit in using hyaluronidase injection after
24 hour.
For this reason, skin necrosis, when occurs, should be treated
immediately with hyaluronidase (in case of HA filler), warm com-
presses and nitroglycerine paste, and, in the case of bad wound out-
comes, a surgical debridement and daily wound care are required to
minimize scarring.
If symptoms of visual impairment occur, the goal is to reduce
intraocular pressure and dislodge the embolus to improve perfu-
sion of the retina and optic nerve. Especially in this case, it is man-
datory to recognize immediately symptoms associated with
vascular embolism of the ophthalmic artery and how to manage
this complication.
Park et al. reported the outcomes of vascular embolism of the
retinal artery after cosmetic filler injections into the glabellar region
or nasolabial fold. Injected autologous fat and HA were associated
with worse final best-corrected visual acuity than the other mate-
rials but the statistical data related to HA were probably due to the
more frequent use of this kind of product. In his experience, all
patients with ophthalmic artery occlusion had ocular pain and no
improvement in best-corrected visual acuity after treatment (Park
et al., 2012).
Even if the unfavorable outcomes in case of visual impairment
after filler injections, the recommended measures include immediate
ophthalmologic consultation, ocular massage, timolol eye drops, diuretics,
hemodilution, corticosteroids, calcium channel blockers, anticoagulation,
and needle decompression of the anterior chamber. For intravascular
infarction after HA filler use, the minimum recommended injection of
hyaluronidase is about 200–300 U of hyaluronidase (spread over the
entire area of impending necrosis), repeated daily for a minimum of
2 days until signs of permanent necrosis or re-established blood flow
appear. However, attempts to reverse retinal artery occlusion are often
unsuccessful (Signorini et al., 2016).
4 | CONCLUSIONS
Even though soft-tissue fillers are generally safe, undesirable
effects can occur with any type of filler. To prevent adverse
events in nonsurgical rhinoplasty, a complete understanding of
anatomy, injection plane, filler properties, and indications for use,
and a complete medical history of the patients are mandatory.
Proper precautions during nonsurgical rhinoplasty should be con-
sidered as syringe aspiration, use of cannula instead of needles,
withdrawal technique, and slow speed of injection with small
amount of product. In addition, patients should be always
informed about all the risks associated with the cosmetic treat-
ment proposed and should be monitored not also during the cos-
metic procedure but after too.
Familiarity with the prevention, presentation, and immediate
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